Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs CubeSmart (CUBE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs CubeSmart — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $286.75 (market cap $39.89B), while CubeSmart trades at $40.45 (market cap $9.10B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.4× CubeSmart's market cap, and CubeSmart pays a 5.27% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | CUBE | |
|---|---|---|
Market Cap | $39.89B | $9.10B |
Sector | Health | Real Estate |
52-Week High | $491.22 | $42.34 |
52-Week Low | $278.09 | $35.36 |
Enterprise Value | $38.15B | $12.60B |
Dividend Yield | — | 5.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
CubeSmart (CUBE) trades at $40.19, up 1.01% with a bearish technical signal despite recent earnings beats. The REIT maintains strong profitability with 28.93% net margins and offers a 5.3% dividend yield. Analyst consensus shows mixed sentiment with 41% buy ratings but a $43.86 price target suggesting 9% upside. Recent news highlights Q2 2026 earnings anticipation on July 30, 2026, while institutional investors have been trimming positions.
The stock presents value with reasonable valuation multiples (P/E 28.1, P/S 8.13) and consistent cash flow generation, though high debt levels and interest rate sensitivity pose risks. Near-term performance will depend on Q2 earnings results and macroeconomic conditions affecting the self-storage sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →
